Laboratory News and Research

RSS

Legal scholar calls for FDA to regulate all health-related genetic tests

An opinion piece by a legal scholar from the Johns Hopkins Berman Institute of Bioethics in this week's issue of Nature calls for the Food and Drug Administration to regulate all health-related genetic tests — whether available directly to consumers or through a health care provider — using an approach that imposes requirements proportionate to a test's level of risk.

13 Aug 2010

U.S. FDA purchases more licenses to Simulations Plus' DDDPlus software

Simulations Plus, Inc., a leading provider of software for pharmaceutical discovery and development, today announced that it has received a purchase order from the U.S. Food and Drug Administration to expand the number of licenses for the Company's DDDPlus™ simulation software.

13 Aug 2010

LabCorp announces collaboration between Esoterix Clinical Trials Services, Clearstone Central Laboratories

Laboratory Corporation of America Holdings announced today a collaboration between Esoterix Clinical Trials Services, a division of LabCorp, and Clearstone Central Laboratories, a global central laboratory specializing in drug development and pharmaceutical services.

13 Aug 2010

Combination of fungi, insecticides can combat malaria mosquitoes: Research

A combination of fungal spores and chemical insecticides are an effective way of combating insecticide-resistant malaria mosquitoes. Researchers at Wageningen UR and from Benin, West Africa, have shown that fungi and insecticides reinforce each other´s efficacy, and that the effect of using a combination of both is greater than the sum of using the two methods separately. Their article in the August edition of PLoS One (Public Library of Science) claims that biological and chemical methods of fighting malaria can and should be used together.

13 Aug 2010

American CareSource second-quarter revenues decrease to $16.0 million

American CareSource Holdings Inc. today announced second quarter 2010 revenues of $16.0 million compared to $17.1 million in the corresponding prior year quarter. Net income for the second quarter 2010 was $299,000, or $0.02 per diluted share, compared to $534,000, or $0.01 per diluted share, in the corresponding prior year quarter. Net income for the second quarter 2010 included a federal income tax provision of $137,000, or $0.01 per diluted share, which was not included in net income for the second quarter 2009.

13 Aug 2010

A*STAR's Singapore Immunology Network, Institut M-rieux and bioM-rieux partner in TB research

An investment of S$3 million is being pumped into tuberculosis (TB) research by A*STAR's Singapore Immunology Network (SIgN), bioindustrial group Institut M-rieux and its in vitro diagnostics company bioM-rieux. The project, which involves setting up a joint laboratory in Biopolis, Singapore aims to investigate and identify novel biomarkers that could allow early identification of individuals at risk of TB disease development and disease reactivation. This could lead to better diagnosis and treatment for the highly contagious disease.

13 Aug 2010

Guided Therapeutics second-quarter service revenue increases to $0.8 million

Guided Therapeutics, Inc. today announced its operating results for the second quarter and first six months of 2010.

13 Aug 2010

U-M dentistry agrees to use Interleukin's PST test for gum disease clinical study

University of Michigan School of Dentistry has signed an agreement with Interleukin Genetics Inc. to conduct what may be the largest clinical study to date using genetic testing to assess the risk for gum disease.

13 Aug 2010

Clearstone Central Laboratories announces strategic global collaboration with LabCorp

Clearstone Central Laboratories, a leading provider of central laboratory services for late-stage clinical trials, announced today a global collaboration with Laboratory Corporation of America® Holdings through its Esoterix Clinical Trials Services division, providing clients with seamless access to CAP-accredited laboratories across both organizations in Belgium, Canada, China, France, Singapore and the United States.

13 Aug 2010

Problems with analytical study design and data misinterpretation leads to biomarker failure: Report

The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article published online August 12 in The Journal of the National Cancer Institute.

13 Aug 2010

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).

13 Aug 2010

Transgenomic second-quarter net loss increases to $1.1 million

Transgenomic, Inc. today reported financial results for the three and six months ended June 30, 2010, and provided a business update.

13 Aug 2010

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

In type 1 diabetes, the body relentlessly attacks and destroys its own insulin-producing pancreatic beta cells. But a study by Joslin Diabetes Center scientists now has firmly established that some of these cells endure for many decades in a small group of people with the disease—offering clues to potential treatments for preserving and even restoring the crucial cell population.

12 Aug 2010

Scientists find new way to prevent potentially harmful plasticizers

Scientists have published the first report on a new way of preventing potentially harmful plasticizers from migrating from one of the most widely used groups of plastics. The advance could lead to a new generation of polyvinyl chloride plastics that are safer than those now used in packaging, medical tubing, toys, and other products, they say. Their study is in ACS' Macromolecules, a bi-weekly journal.

12 Aug 2010

NPL CaviMeter fine-tunes equipment to produce right quantity and distribution of cleaning action

Ultrasonic Cleaning Systems are widely used in healthcare applications during the sterilization of surgical instruments, and in many manufacturing and process industries. They work by passing a high frequency sound wave through a liquid detergent to create thousands of small bubbles. The sound waves then makes the bubbles implode with such force, that the impacts remove contaminant particles from submerged materials.The current NHS-recommended technique to measure the performance of ultrasonic cleaning systems uses aluminium foil, which is eroded and punctured by the imploding bubbles. This is an unreliable process to apply and can contaminate the vessel cleaning fluid, adding unnecessary costs.

12 Aug 2010

Numerate collaborates with Intellikine to identify drug-like inhibitors of PI3 kinase alpha

Numerate, Inc. and Intellikine, Inc. today announced the successful conclusion of their research collaboration to discover novel small molecule compounds targeting the PI3K/mTOR signaling pathway. The collaboration combined Intellikine's unique capabilities in x-ray crystal structure-guided medicinal chemistry and drug discovery with Numerate's powerful computational drug design platform to identify potent, selective and drug-like inhibitors of PI3 kinase alpha, an important target in cancer therapy.

12 Aug 2010

Study shows change in training can reduce ACL tears in female athletes

Anterior cruciate ligament injuries are a common and debilitating problem, especially for female athletes. A new study from UC Davis shows that changes in training can reduce shear forces on knee joints and could help cut the risk of developing ACL tears. The research was published online Aug. 3 in the Journal of Biomechanics.

12 Aug 2010

Somaxon second-quarter net loss reduces to $5.7 million

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the second quarter ended June 30, 2010.

12 Aug 2010

AdvanDx announces European launch of CE-IVD marked GNR Traffic Light PNA FISH test

AdvanDx today announced the launch of its CE-IVD marked GNR Traffic Light™ PNA FISH® test in Europe. GNR Traffic Light PNA FISH is the first-ever test capable of simultaneously identifying Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa directly from positive blood cultures in less than 90 minutes.

12 Aug 2010

Intellect Neurosciences receives patent for insulin sensitizer drugs

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that its Chairman & CEO, Dr. Daniel Chain, was granted a patent by the European Patent and Trademark Office related to the use of insulin sensitizers for the prevention and treatment of memory loss and dementia. Insulin sensitizer drugs include Rosiglitazone and Pioglitazone, which have been approved for the treatment of type II diabetes mellitus.

12 Aug 2010

Laboratory News and Research

Legal scholar calls for FDA to regulate all health-related genetic tests

U.S. FDA purchases more licenses to Simulations Plus' DDDPlus software

LabCorp announces collaboration between Esoterix Clinical Trials Services, Clearstone Central Laboratories

Combination of fungi, insecticides can combat malaria mosquitoes: Research

American CareSource second-quarter revenues decrease to $16.0 million

A*STAR's Singapore Immunology Network, Institut M-rieux and bioM-rieux partner in TB research

Guided Therapeutics second-quarter service revenue increases to $0.8 million

U-M dentistry agrees to use Interleukin's PST test for gum disease clinical study

Clearstone Central Laboratories announces strategic global collaboration with LabCorp

Problems with analytical study design and data misinterpretation leads to biomarker failure: Report

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Transgenomic second-quarter net loss increases to $1.1 million

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

Scientists find new way to prevent potentially harmful plasticizers

NPL CaviMeter fine-tunes equipment to produce right quantity and distribution of cleaning action

Numerate collaborates with Intellikine to identify drug-like inhibitors of PI3 kinase alpha

Study shows change in training can reduce ACL tears in female athletes

Somaxon second-quarter net loss reduces to $5.7 million

AdvanDx announces European launch of CE-IVD marked GNR Traffic Light PNA FISH test

Intellect Neurosciences receives patent for insulin sensitizer drugs

Lab Diagnostics and Automation - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News